Shefali Agarwal
Algemeen Directeur bij VALERIO THERAPEUTICS
Vermogen: 40 596 $ op 30-04-2024
Actieve functies van Shefali Agarwal
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| FATE THERAPEUTICS, INC. | Directeur/Bestuurslid | 15-07-2019 | - |
| Independent Dir/Board Member | 15-07-2019 | - | |
| GRITSTONE BIO, INC. | Directeur/Bestuurslid | 01-06-2021 | - |
| Independent Dir/Board Member | 01-06-2021 | - | |
| VALERIO THERAPEUTICS | Voorzitter | 29-07-2021 | - |
| Algemeen Directeur | 06-04-2022 | - | |
| President | 06-04-2022 | - | |
| Directeur/Bestuurslid | 01-06-2021 | 29-07-2021 | |
| Independent Dir/Board Member | 01-06-2021 | 29-07-2021 |
Loopbaan van Shefali Agarwal
Eerdere bekende functies van Shefali Agarwal
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EPIZYME, INC. | Hoofd Techniek/Wetenschap/O&O | 01-06-2018 | 06-04-2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Hoofd Techniek/Wetenschap/O&O | 01-07-2017 | 01-05-2018 |
Opleiding van Shefali Agarwal
| Karnataka University | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Merrick School of Business | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
| India | 2 |
| Frankrijk | 2 |
Operationeel
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
| Health Technology | 6 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Shefali Agarwal
- Ervaring
